Two recent studies report deep molecular profiling of matched brain metastases and primary tumors. In both studies, somatic alterations in the brain metastases were frequently discordant with those in the primary tumor, suggesting divergent evolution at metastatic sites and raising questions about the use of biomarkers in patients in clinical trials with targeted therapies.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Nov 2015|
ASJC Scopus subject areas